A Phase 1 Study of OCV-C02 in Patients With Advanced or Relapsed Colorectal Cancer Who Are Refractory or Intolerant to Standard Chemotherapy
Phase of Trial: Phase I
Latest Information Update: 21 Jan 2017
At a glance
- Drugs OCV C02 (Primary)
- Indications Colorectal cancer
- Focus Adverse reactions
- Sponsors Otsuka Pharmaceutical
- 21 Jan 2017 Results presented at the 2017 Gastrointestinal Cancers Symposium.
- 23 Sep 2016 Status changed from active, no longer recruiting to completed.
- 01 Apr 2016 Planned End Date changed from 1 Dec 2015 to 1 May 2016 as per ClinicalTrials.gov record.